130 related articles for article (PubMed ID: 33429737)
1. The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma.
Byun JM; Cho HJ; Park HY; Lee DS; Choi IH; Kim YN; Jeong CH; Kim DH; Hwa Im D; Min BJ; Lee KB; Sung MS; Jeong DH
Medicine (Baltimore); 2021 Jan; 100(1):e23691. PubMed ID: 33429737
[TBL] [Abstract][Full Text] [Related]
2. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
3. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
Liao X; Zhang D
Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
[TBL] [Abstract][Full Text] [Related]
4. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
5. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
[TBL] [Abstract][Full Text] [Related]
6. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
7. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
Long L; Zhang L; Yang Y; Zhou Y; Chen H
Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955
[No Abstract] [Full Text] [Related]
8. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
9. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
10. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population.
Zhang C; Xu J; Ye J; Zhang X
Medicine (Baltimore); 2021 Jul; 100(30):e26789. PubMed ID: 34397730
[TBL] [Abstract][Full Text] [Related]
13. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
14. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance.
Gawesh ZM; Ibrahim EM; ElKalla HMHR; Awad AAH; Mohamed MA
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4309-4319. PubMed ID: 38156868
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mismatch repair and immune checkpoint protein profile with histopathological parameters in pancreatic, periampullary/ampullary, and choledochal adenocarcinomas.
Aydın AH; Turhan N
World J Gastrointest Oncol; 2024 Mar; 16(3):875-882. PubMed ID: 38577456
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.
Wei L; Tang L; Chang H; Huo S; Li Y
Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567
[TBL] [Abstract][Full Text] [Related]
18. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.
Yan H; Qiu W; Koehne de Gonzalez AK; Wei JS; Tu M; Xi CH; Yang YR; Peng YP; Tsai WY; Remotti HE; Miao Y; Su GH
Cancer Lett; 2019 Feb; 442():333-340. PubMed ID: 30447255
[TBL] [Abstract][Full Text] [Related]
19. HHLA2 is more significantly associated with poor prognosis in TSCC than PD-L1.
Li Y; Yang Q; Yang X; Ge J; Xu T; Liu H
J Oral Pathol Med; 2024 Feb; 53(2):159-168. PubMed ID: 38321252
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
Zhang X; Qin Y; Chen X; Xiong M; Shu S
Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
[No Abstract] [Full Text] [Related]
[Next] [New Search]